Additionally, HER2 amplification detected on tissue or on circulating tumor DNA (ctDNA) was identified as a possible mechanism of acquired resistance in HER2 negative, RAS/BRAF WT, patients progressed during anti-EGFR treatment[135]. The gene discussed is EGFR; the disease is neoplasm.